Trimetazidine | Trimetazidine-Teva tablets are coated.pl.ob. 20 mg 60 pcs.

Release form

film-coated tablets.

Packing

60 pcs.

Pharmacological action

Trimetazidine antihypoxic drug. It has an antianginal, antihypoxic effect. Directly affecting cardiomyocytes and brain neurons, it optimizes their metabolism and function. The cytoprotective effect is due to an increase in the energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). It supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinin. Under conditions of acidosis, it normalizes the functioning of membrane ion channels and prevents the accumulation of calcium and sodium in cardiomyocytes. normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate levels due to myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, maintains the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, increases the duration of the electric potential, reduces the yield of creatine phosphokinase from the cells and the severity of ischemic damage to the myocardium.

With angina pectoris it reduces the frequency of seizures (nitrate intake decreases), after 2 weeks of treatment, exercise tolerance increases, and blood pressure drops decrease. Hearing and results of vestibular tests in patients improve, dizziness and tinnitus decrease.

With vascular pathology, the eye restores the functional activity of the retina.

Indications

Coronary heart disease: prevention of angina attacks (in complex therapy): Chorioretinal vascular disorders

Dizziness of vascular origin

Cochleo-vestibular disorders of ischemic nature (tinnitus, hearing impairment).

Contraindications

Hypersensitivity to any component of the

preparation Renal failure (creatinine clearance below 15 ml / min)

Severe hepatic dysfunction

Pregnancy

Breastfeeding period: Safety and under 18 years of age (established).

Use during pregnancy and lactation

Trimetazidine is contraindicated during pregnancy due to the lack of clinical data on the safety of its use. If necessary, the appointment of the drug during lactation should stop breastfeeding. It is not known whether trimetazidine is excreted in breast milk. In experimental studies, the teratogenic effect of trimetazidine has not been established.

Special instructions

A significant decrease in the daily requirement for nitrates occurs during treatment with the drug in patients with coronary heart disease.

The use of the drug does not affect the ability to drive a car and perform work requiring a high speed of mental and physical reactions.

Composition

1 tablet, coated, contains

active substance:

solifenacin succinate 5 mg

excipients:

lactose monohydrate

starch corn srdlkmp1 mrd41mdpf101aaaaaaaaaaaaaaaaaaaaaaaaaaa coated, contains the active substance trimetazidine dihydrochloride 20 mg

Dosage and Administration

Inside, with meals.

Recommended dosage 2-3 tablets (40-60 mg) per day, in 2-3 doses. The course of treatment is recommended by a doctor.

Side effects

Allergic reactions (pruritus).

Rarely from the gastrointestinal tract: gastralgia. nausea, vomiting, headache, palpitations.

Storage conditions

In a dry, dark place at a temperature of no higher than 25 РC. Keep out of the reach of children.

Expiration

3 years.

Form of Treatment

tablets

Indications

Angina

Teva Pharmaceutical Enterprises Co., Ltd., Israel